drugset / Trial / NCT03541603

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

NCT03541603

Phase 2 Completed 44 enrolled Tenax Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects

Timeline

Start
2018-11-14
Primary completion
2020-04-07
Completion
2020-04-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Levosimendan Other / unclassified 0.075 ug/kg Intravenous
Subject Levosimendan Other / unclassified 0.1 ug/kg Intravenous